Literature DB >> 11718260

New animal models to probe brain tumor biology, therapy, and immunotherapy: advantages and remaining concerns.

L A Lampson1.   

Abstract

New genetic models provide better biological mimics of human tumors. The new models can give deeper insight into tumorigenesis and provide better targets for testing therapies. To use the new models most successfully, it is useful to keep in mind limitations that are harder to overcome by genetic manipulation. These include biochemical and anatomical differences between species, as well as differences in scale, both spatial and temporal. Three approaches to new genetic brain tumor models are described in the following articles. This essay provides a context, bringing out both advantages and remaining concerns. Examples are taken from work in brain tumor immunobiology and immunotherapy. The complementarity of different models, and the dichotomy between general principles and model-specific details are stressed.

Entities:  

Mesh:

Year:  2001        PMID: 11718260     DOI: 10.1023/a:1012230113527

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  26 in total

1.  Local immune regulation in the central nervous system by substance P vs. glutamate.

Authors:  L P McCluskey; L A Lampson
Journal:  J Neuroimmunol       Date:  2001-06-01       Impact factor: 3.478

2.  Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement.

Authors:  L A Lampson; W F Hickey
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

Review 3.  Beyond inflammation: site-directed immunotherapy.

Authors:  L A Lampson
Journal:  Immunol Today       Date:  1998-01

4.  Exploiting the lacZ reporter gene for quantitative analysis of disseminated tumor growth within the brain: use of the lacZ gene product as a tumor antigen, for evaluation of antigenic modulation, and to facilitate image analysis of tumor growth in situ.

Authors:  L A Lampson; M A Lampson; A D Dunne
Journal:  Cancer Res       Date:  1993-01-01       Impact factor: 12.701

Review 5.  Enhanced T cell migration to sites of microscopic CNS disease: complementary treatments evaluated by 2- and 3-D image analysis.

Authors:  L A Lampson; A Chen; A O Vortmeyer; A E Sloan; Z Ghogawala; L Kim
Journal:  Brain Pathol       Date:  1994-04       Impact factor: 6.508

6.  Central nervous system lymphoma in the acquired immunodeficiency syndrome.

Authors:  S Morgello; C K Petito; J A Mouradian
Journal:  Clin Neuropathol       Date:  1990 Jul-Aug       Impact factor: 1.368

7.  Site-specific immune regulation in the brain: differential modulation of major histocompatibility complex (MHC) proteins in brainstem vs. hippocampus.

Authors:  L M Phillips; P J Simon; L A Lampson
Journal:  J Comp Neurol       Date:  1999-03-15       Impact factor: 3.215

8.  Disseminating tumor cells and their interactions with leukocytes visualized in the brain.

Authors:  L A Lampson; P Wen; V A Roman; J H Morris; J A Sarid
Journal:  Cancer Res       Date:  1992-02-15       Impact factor: 12.701

9.  Immune modulation within the brain: recruitment of inflammatory cells and increased major histocompatibility antigen expression following intracerebral injection of interferon-gamma.

Authors:  M P Sethna; L A Lampson
Journal:  J Neuroimmunol       Date:  1991-11       Impact factor: 3.478

10.  Long term survivors of childhood brain stem gliomas treated with hyperfractionated radiotherapy. Clinical characteristics and treatment related toxicities. The Pediatric Oncology Group.

Authors:  C R Freeman; P M Bourgouin; R A Sanford; M E Cohen; H S Friedman; L E Kun
Journal:  Cancer       Date:  1996-02-01       Impact factor: 6.860

View more
  11 in total

Review 1.  The status of gene therapy for brain tumors.

Authors:  Giulia Fulci; E Antonio Chiocca
Journal:  Expert Opin Biol Ther       Date:  2007-02       Impact factor: 4.388

Review 2.  Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas.

Authors:  Rolf F Barth; Balveen Kaur
Journal:  J Neurooncol       Date:  2009-04-21       Impact factor: 4.130

3.  Improved rodent models of human brain metastases.

Authors:  Edward Henry Mathews; Leon Liebenberg
Journal:  Clin Exp Metastasis       Date:  2013-05-18       Impact factor: 5.150

Review 4.  Gene therapy and targeted toxins for glioma.

Authors:  Maria G Castro; Marianela Candolfi; Kurt Kroeger; Gwendalyn D King; James F Curtin; Kader Yagiz; Yohei Mineharu; Hikmat Assi; Mia Wibowo; A K M Ghulam Muhammad; David Foulad; Mariana Puntel; Pedro R Lowenstein
Journal:  Curr Gene Ther       Date:  2011-06       Impact factor: 4.391

Review 5.  Gene therapy and targeted toxins for glioma.

Authors:  Gwendalyn D King; James F Curtin; Marianela Candolfi; Kurt Kroeger; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Gene Ther       Date:  2005-12       Impact factor: 4.391

6.  Naringenin promote apoptosis in cerebrally implanted C6 glioma cells.

Authors:  Devan Sabarinathan; Palani Mahalakshmi; Arambakkam Janardhanam Vanisree
Journal:  Mol Cell Biochem       Date:  2010-08-18       Impact factor: 3.396

7.  Brainstem glioma progression in juvenile and adult rats.

Authors:  Qing Liu; Ran Liu; Meghana V Kashyap; Rajnee Agarwal; Xiang'en Shi; Chung-cheng Wang; Shao-Hua Yang
Journal:  J Neurosurg       Date:  2008-11       Impact factor: 5.115

8.  Robust ability of IFN-gamma to upregulate class II MHC antigen expression in tumor bearing rat brains.

Authors:  Tanya Dutta; Alexander Spence; Lois A Lampson
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

Review 9.  Brain tumor immunotherapy: an immunologist's perspective.

Authors:  Lois A Lampson
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

Review 10.  Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier.

Authors:  Lois A Lampson
Journal:  MAbs       Date:  2011-03-01       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.